MediLink Therapeutics’ YL201 Receives FDA Orphan Drug Designation for Small-Cell Lung Cancer
Suzhou-based biotech company MediLink Therapeutics (Suzhou) Co., Ltd has announced that the US Food and...
BMS Regains Exclusive Rights to ABZ-706 in Greater China
Bristol-Myers Squibb (BMS; NYSE: BMY) has reached an agreement with China-based Ablaze Pharmaceuticals to regain...
Everest Medicines’ Nefecon Receives First Prescription for IgAN Treatment in Adults
China-based Everest Medicines (HKG: 1952) has announced that its targeted-release budesonide, Nefecon, has been prescribed...
FDA Approves Xcovery Holdings’ Ensartinib for Untreated ALK-Positive NSCLC Patients
On December 18, 2024, the Food and Drug Administration (FDA) granted approval for Betta Pharmaceutical...
INT Medical Instruments to Acquire Controlling Stake in Weiqiang Medical Technology for RMB 230 Million
Shanghai INT Medical Instruments Co., Ltd. (HKG: 1501) has announced its intention to acquire at...
Janssen-Cilag Submits for IMBRUVICA Indication Extension in Untreated Mantle Cell Lymphoma
Janssen-Cilag International NV has announced the submission seeking approval for an indication extension of IMBRUVICA...
iFlytek’s Subsidiary Xunfei Healthcare Technologies Lists on HKEX, Raises Over HKD 580 Million
Xunfei Healthcare Technology Co., Ltd, a subsidiary of China-based information technology company iFlytek Co., Ltd...
Chengdu Kanghua Biological Receives NMPA Approval for Recombinant Norovirus Vaccine
Chengdu Kanghua Biological Products Co., Ltd, (SHE: 300841), a leading biopharmaceutical company based in China,...
Sinocare Inc’s TRUE VIE CGMS Advances to 510(k) Substantive Review Stage at FDA
Sinocare Inc (SHE: 300298), a China-based medical technology company, has announced that its continuous glucose...
Huadong Medicine’s HDM1005 Receives FDA Clearance for Heart Failure and Obesity Clinical Trial
China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced that it has received clearance from...
Jiangsu Hengrui Pharmaceuticals Gets NMPA Approval for SHR-1501 Combo in Bladder Cancer
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276), a leading China-based pharmaceutical company, has announced that...
Sino Biopharmaceutical’s Benmelstobart Meets Primary Endpoint in Phase III NSCLC Study
Sino Biopharmaceutical Ltd (HKG: 1177), a leading China-based biopharmaceutical company, has announced positive results from...
Hansoh Pharmaceutical Secures Global Licensing Deal with Merck for HS-10535
China’s Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) has announced a significant global license deal...
Ascletis Pharma’s ASC47 Outperforms Semaglutide in Weight Loss Study
China-based Ascletis Pharma Inc. (HKG: 1672) has announced encouraging results from a study on its...
UCB’s Minzasolmin Fails to Meet Endpoints in ORCHESTRA Study for Early Parkinson’s
Belgium-based biopharmaceutical company UCB (EBR: UCB) has announced the disappointing results of the ORCHESTRA proof-of-concept...
HealthyWay Inc. Completes HKD 220 Million IPO on the Hong Kong Stock Exchange
China-based HealthyWay Inc. (HKG: 2587) has made a significant debut on the Hong Kong Stock...
Sino Biopharmaceutical and Sinopharm Group Collaborate to Expand Retail Pharmacy Network
In a significant move for China’s pharmaceutical industry, Sino Biopharmaceutical Ltd (HKG: 1177) and Sinopharm...
Everest Medicines’ Velsipity (Etrasimod) Receives First Prescription in Foshan under GBA Policy
Everest Medicines (HKG: 1952), a leading biopharmaceutical company based in China, has announced that its...
ImmuneOnco Biopharmaceuticals Initiates Phase Ib Study for Amulirafusp Alfa in NMOSD
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKG: 1541), a China-based biopharmaceutical company, has announced the commencement of...
Henlius Biotech Joins Biosimilars Forum to Expand Global Biosimilars Access
Shanghai Henlius Biotech Inc. (HKG: 2696), a leading Chinese biopharmaceutical company, has announced its membership...